Karyopharm Therapeutics (NASDAQ:KPTI) Given Buy Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) in a research note released on Wednesday morning, Benzinga reports. They currently have a $7.00 price target on the stock. Other equities research analysts also recently issued reports about the stock. Robert W. Baird cut their target price on shares […]
More Stories
EBay Turns Down GameStop’s $55.5 Billion Takeover Proposal
By Andrew Moran EBay has turned down videogame retailer GameStop’s $55.5 billion takeover proposal. The online marketplace, in a May...
Trump Nominates Lake, Mastriano to Diplomatic Posts
By Kimberly Hayek President Donald Trump on Monday announced a slew of nominations sent to the U.S. Senate, including two...
Treasury Department Alerts US Banks to Suspected Iranian Money Laundering Efforts
By Victoria Friedman The U.S. Treasury Department’s Financial Crimes Enforcement Network (FinCEN) on May 11 issued an alert to financial...
Gas Prices Lift US Annual Inflation Rate to 3.8 Percent Highest Since May 2023
By Andrew Moran Consumer prices accelerated for the second straight month in April as the war in Iran added to...
Canadians Increasingly Favor Economic Growth Over Environmental Stewardship in Energy Policy: Poll
By William Hetherington Canadians are increasingly prioritizing economic growth over environmental protection in energy policy decisions, with support for new...
Record 45 Million Americans Expected to Travel Over Memorial Day Weekend: AAA
By Mary Prenon Despite rising gas prices, more than 45 million Americans are expected to hit the road, fly, or...